Developing lab research into the foundations of a profitable biotech company has always been a high-risk, high-reward business.
Deerfield Management, a New York-based healthcare investor with more than $5 billion under management and two decades of experience, has created a new $550 million fund that targets early stage science from academic medical centers and hospitals. The fund is specifically focused on innovative treatments for genetic disorders, cancer, and orphan diseases.
{iframe}http://www.xconomy.com/new-york/2015/07/28/with-550m-fund-deerfield-management-tackles-early-stage-biotech/?utm_source=Xconomy&utm_campaign=bacc49a6b5-NEWSLETTER_all_stories&utm_medium=email&utm_term=0_2aa91c0bc9-bacc49a6b5-288460969{/iframe}